Liver cancer patients see longer survival with dual immunotherapy approach

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a ‘dual immunotherapy’ combination—nivolumab and ipilimumab (NIVO+IPI)—in the treatment of liver cancer patients since 2016.

Go to Source
https://medicalxpress.com/rss-feed/

Top